141 related articles for article (PubMed ID: 38134241)
1. KCNN4 links PIEZO-dependent mechanotransduction to NLRP3 inflammasome activation.
Ran L; Ye T; Erbs E; Ehl S; Spassky N; Sumara I; Zhang Z; Ricci R
Sci Immunol; 2023 Dec; 8(90):eadf4699. PubMed ID: 38134241
[TBL] [Abstract][Full Text] [Related]
2. Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome.
Karasawa T; Komada T; Yamada N; Aizawa E; Mizushina Y; Watanabe S; Baatarjav C; Matsumura T; Takahashi M
Elife; 2022 May; 11():. PubMed ID: 35616535
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome.
Theodoropoulou K; Spel L; Zaffalon L; Delacrétaz M; Hofer M; Martinon F
J Allergy Clin Immunol; 2023 Jan; 151(1):222-232.e9. PubMed ID: 36075321
[TBL] [Abstract][Full Text] [Related]
4. Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.
Frising UC; Ribo S; Doglio MG; Malissen B; van Loo G; Wullaert A
EMBO Rep; 2022 Jul; 23(7):e54339. PubMed ID: 35574994
[TBL] [Abstract][Full Text] [Related]
5. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP.
Lee GS; Subramanian N; Kim AI; Aksentijevich I; Goldbach-Mansky R; Sacks DB; Germain RN; Kastner DL; Chae JJ
Nature; 2012 Dec; 492(7427):123-7. PubMed ID: 23143333
[TBL] [Abstract][Full Text] [Related]
6.
Nakanishi H; Kawashima Y; Kurima K; Chae JJ; Ross AM; Pinto-Patarroyo G; Patel SK; Muskett JA; Ratay JS; Chattaraj P; Park YH; Grevich S; Brewer CC; Hoa M; Kim HJ; Butman JA; Broderick L; Hoffman HM; Aksentijevich I; Kastner DL; Goldbach-Mansky R; Griffith AJ
Proc Natl Acad Sci U S A; 2017 Sep; 114(37):E7766-E7775. PubMed ID: 28847925
[TBL] [Abstract][Full Text] [Related]
7. CANE, a Component of the NLRP3 Inflammasome, Promotes Inflammasome Activation.
Kaneko N; Kurata M; Yamamoto T; Sakamoto A; Takada Y; Kosako H; Takeda H; Sawasaki T; Masumoto J
J Immunol; 2024 Jul; 213(1):86-95. PubMed ID: 38787200
[TBL] [Abstract][Full Text] [Related]
8. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations.
Mortimer L; Moreau F; MacDonald JA; Chadee K
Nat Immunol; 2016 Oct; 17(10):1176-86. PubMed ID: 27548431
[TBL] [Abstract][Full Text] [Related]
9. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux.
He Y; Zeng MY; Yang D; Motro B; Núñez G
Nature; 2016 Feb; 530(7590):354-7. PubMed ID: 26814970
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.
Moltrasio C; Romagnuolo M; Marzano AV
Front Immunol; 2022; 13():1007705. PubMed ID: 36275641
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of NLRP3 inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model.
Ma JH; Lee E; Yoon SH; Min H; Oh JH; Hwang I; Sung Y; Ryu JH; Bok J; Yu JW
EBioMedicine; 2022 Aug; 82():104184. PubMed ID: 35870427
[TBL] [Abstract][Full Text] [Related]
12. Piezo1 activates the NLRP3 inflammasome in nucleus pulposus cell-mediated by Ca
Sun Y; Leng P; Song M; Li D; Guo P; Xu X; Gao H; Li Z; Li C; Zhang H
Int Immunopharmacol; 2020 Aug; 85():106681. PubMed ID: 32526681
[TBL] [Abstract][Full Text] [Related]
13. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
14. Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis.
Zeng B; Huang Y; Chen S; Xu R; Xu L; Qiu J; Shi F; Liu S; Zha Q; Ouyang D; He X
Cell Mol Immunol; 2022 Aug; 19(8):925-943. PubMed ID: 35799057
[TBL] [Abstract][Full Text] [Related]
15. CAPS and NLRP3.
Booshehri LM; Hoffman HM
J Clin Immunol; 2019 Apr; 39(3):277-286. PubMed ID: 31077002
[TBL] [Abstract][Full Text] [Related]
16. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants.
Rieber N; Gavrilov A; Hofer L; Singh A; Öz H; Endres T; Schäfer I; Handgretinger R; Hartl D; Kuemmerle-Deschner J
Clin Immunol; 2015 Mar; 157(1):56-64. PubMed ID: 25596455
[TBL] [Abstract][Full Text] [Related]
17. Increased Prevalence of
Theodoropoulou K; Wittkowski H; Busso N; Von Scheven-Gête A; Moix I; Vanoni F; Hengten V; Horneff G; Haas JP; Fischer N; Palm-Beden K; Berendes R; Heubner G; Jansson A; Lainka E; Leimgruber A; Morris M; Foell D; Hofer M
Front Immunol; 2020; 11():877. PubMed ID: 32477355
[No Abstract] [Full Text] [Related]
18. Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC.
Sušjan P; Lainšček D; Strmšek Ž; Hodnik V; Anderluh G; Hafner-Bratkovič I
FASEB J; 2020 Aug; 34(8):11068-11086. PubMed ID: 32648626
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production.
Molina-López C; Hurtado-Navarro L; García CJ; Angosto-Bazarra D; Vallejo F; Tapia-Abellán A; Marques-Soares JR; Vargas C; Bujan-Rivas S; Tomás-Barberán FA; Arostegui JI; Pelegrin P
Nat Commun; 2024 Feb; 15(1):1096. PubMed ID: 38321014
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx.
Katsnelson MA; Lozada-Soto KM; Russo HM; Miller BA; Dubyak GR
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C83-C100. PubMed ID: 27170638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
